Replimune Group, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors on October 31, 2026. There are 8 upcoming events on record.
Cash runway is approximately 7.7 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.